Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Summary

This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and post-transplant. The primary end point will be tetanus vaccine immune responses post-transplant.

Timeline

Start

2020-01-09

Primary completion

2022-12-21

Completion

2022-12-21

Drugs

Indications